## Abstract ## BACKGROUND Based on preclinical findings and on the clinical antitumor efficacy of sequential paclitaxel/topotecan and topotecan/etoposide, the authors sought to define the maximum tolerated doses (MTDs) and doseβlimiting toxicities (DLTs) associated with a sequential combination of
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors
β Scribed by David S. Hong; James L. Abbruzzese; Karla Bogaard; Yvonne Lassere; Masakazu Fukushima; Akira Mita; Keizo Kuwata; Paulo M. Hoff
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 176 KB
- Volume
- 107
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Photodynamic therapy (PDT) currently is approved for the palliative treatment of malignancies of the aerodigestive tract using laserβactivated porfimer sodium. A new approach has been developed, based on intratumoral placement of a nonlaser light device that activates tal
## BACKGROUND. Compared with free drug, sterically stabilized liposomal drug has prolonged circulation time and, thereby, higher tumor selectivity and antitumor activity. The stability in plasma is an important consideration in the formulation of clinically useful liposomal drug. A Phase I study o
## Abstract ## BACKGROUND Topotecan (9βdimethylaminomethylβ10βhydroxycampthothecin) is a new topoisomerase I inhibitor with promising efficacy in the treatment of patients with small cell lung carcinoma (SCLC). Combination with a topoisomerase II inhibitor may potentate the therapeutic effect of t